ENDRA Life Sciences Inc. (NDRA): Nasdaq/NYSE listing notice — ENDRA Life Sciences receives Nasdaq bid price deficiency notice; has until Oct 30 to regain compliance

ENDRA Life Sciences Inc.

Received Nasdaq notice on May 3, 2024 for closing bid price below $1.00 for 30 consecutive trading days.
Has 180 calendar days, until October 30, 2024, to regain compliance with Minimum Bid Price Requirement.
To cure: bid price must close at or above $1.00 for at least 10 consecutive business days before deadline.
If not cured by Oct 30, may qualify for additional 180-day period if it meets other listing standards.
Company intends to monitor bid price and consider options including a potential reverse stock split.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

ENDRA Life Sciences Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

May 3, 2024, ENDRA Life Sciences Inc. (the “Company”) received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, because the closing bid price for the Company’s common stock listed on Nasdaq was below $1.00 for 30 consecutive trading days, the Company no longer meets the minimum bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Marketplace Rule 5550(a)(2), requiring a minimum bid price of $1.00 per share (the “Minimum Bid Price Requirement”). The notification has no immediat

View on SEC.gov

97 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

ENDRA Life Sciences Inc. filing history →

Source: SEC EDGAR

accession 0001654954-24-005552

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.